Fulcrum Holders Get About 5% Of Slate Deal Plus A $270 Million Dividend, Amended Filing Shows
The S-4/A for the pending Slate Medicines merger leaves the reverse split ratio blank and sets an estimated exchange ratio of about 24.8186.
Fulcrum Therapeutics holders would own about 5.0% of the combined company and receive a pre-closing cash dividend of about $270 million under the pending merger with Slate Medicines, according to Amendment No. 2 to the S-4 filed Tuesday. The registration statement still leaves the reverse stock split ratio blank, though the split is needed to meet Nasdaq's $4.00 minimum bid price for a new listing.
The ownership and cash math
Slate holders excluding the new investors would own about 55.9% of the combined company on a fully diluted basis. Concurrent investors, who are putting in about $245.0 million immediately before closing, would hold about 39.1%.
The estimated exchange ratio is about 24.8186 Fulcrum shares per Slate share, before the reverse split. The ratio is fixed apart from a net cash adjustment, with no collar and no price-based right to walk away. If Fulcrum's net cash falls below $20.3 million, Slate holders get more shares.
The filing values Slate at $350 million before the investment and Fulcrum at $31.3 million. That is $20.3 million of net cash plus an $11 million non-cash enterprise value.
Leerink, Fulcrum's financial adviser, puts the consideration at $3.93 per share, made up of a $3.52 dividend and $0.41 for the retained share. Its present value of $3.84 compares with a dissolution value of $3.78 per share.
Why Fulcrum chose this deal
Fulcrum discontinued its pociredir program over FDA concerns and cut headcount by about 85%, according to the filing. Its board contacted 62 counterparties, received 13 indications of interest and prioritized 6 before picking Slate.
Slate's first proposal valued Fulcrum at $10 million. It was later raised to $31.3 million. Rival bidders offered Fulcrum holders between 1.9% and 13.0% ownership.
Slate is a clinical-stage migraine company. Its lead antibody is licensed from DartsBio, with up to $54.5 million of development milestones and $988 million of commercial milestones.
The catch: a blank split and a thin share price cushion
Fulcrum closed at $3.74 on August 14, 2026 and $3.70 on October 19, 2026, both below the $4.00 listing threshold. The filing does not fill in the ratio, which the parties are to agree.
The combined company would be renamed Slate Medicines and expected to trade as SLTE. All six board seats go to Slate designees, including Mark W. Hahn as chair and Gregory Oakes, who would be CEO. All current Fulcrum directors resign and its executives are terminated at closing with severance.
Termination fees run $10 million payable by Fulcrum and $15 million payable by Slate in specified cases. The outside date is February 28, 2027.
What comes next
The HSR antitrust waiting period expired September 28, 2026, and the filing expects closing in the fourth quarter. The S-4 must still be declared effective. Slate holders then have two business days to deliver written consent, and Fulcrum must hold its vote within 45 days. Nasdaq must also approve the listing.
Fulcrum had 76,381,948 shares outstanding at September 30, 2026, and its meeting date is still blank in the filing.